Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology, and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
MCPHS provides an academic environment to guide and support fellows toward a successful career in the biopharmaceutical industry. As a private institution with a history of specializing in health sciences, MCPHS offers programs that embody scholarship, professional service, and community outreach.
Through MCPHS, the fellow will have the opportunity to gain teaching and research experience in an academic setting. MCPHS faculty and company... program leaders mentor fellows according to their scholarly and professional interests throughout the two-year program.
As an adjunct instructor at MCPHS, the fellow may have the opportunity to:
• Develop, coordinate, and teach courses
• Co-precept pharmacy students on advanced experiential rotations
• Create and publish scholarly research and/or review articles
• Present research at scientific and clinical meetings
• Participate in professional development seminars with other fellows and residents from MCPHS-affiliated programs